238 related articles for article (PubMed ID: 12722017)
1. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
Calvert H
Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
[TBL] [Abstract][Full Text] [Related]
2. Review of a promising new agent--pemetrexed disodium.
Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed disodium (Eli Lilly).
Norman P
Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Jones RJ; Twelves CJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
[TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
9. [Pemetrexed: from preclinic to clinic].
Lansiaux A; Lokiec F
Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
[TBL] [Abstract][Full Text] [Related]
10. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
Molina JR; Adjei AA
Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
[TBL] [Abstract][Full Text] [Related]
11. [Pemetrexed].
Sudoh J; Gemma A
Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed: a novel antifolate agent enters clinical practice.
Kut V; Patel JD; Argiris A
Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.
Gomez HL; Santillana SL; Vallejos CS; Velarde R; Sanchez J; Wang X; Bauer NL; Hockett RD; Chen VJ; Niyikiza C; Hanauske AR
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):832-8. PubMed ID: 16467096
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed: translational research in breast cancer.
Hanauske AR
Semin Oncol; 2002 Jun; 29(3 Suppl 9):40-2. PubMed ID: 12094337
[TBL] [Abstract][Full Text] [Related]
16. Clinical Experience With Pemetrexed in Breast Cancer.
Martin M
Semin Oncol; 2006 Feb; 33(Suppl 2):S15-8. PubMed ID: 16472713
[TBL] [Abstract][Full Text] [Related]
17. Overview of phase II trials of MTA in solid tumors.
O'Dwyer PJ; Nelson K; Thornton DE
Semin Oncol; 1999 Apr; 26(2 Suppl 6):99-104. PubMed ID: 10598563
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Bunn PA
Semin Oncol; 2002 Jun; 29(3 Suppl 9):17-22. PubMed ID: 12094334
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed: an active new agent for breast cancer.
O'Shaughnessy JA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):57-62. PubMed ID: 12571813
[TBL] [Abstract][Full Text] [Related]
20. Biochemical pharmacology of pemetrexed.
Calvert AH
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
